Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3371237 | 0.99 | CNR2 (0.50) | SLC6A2SLC6A3CNR2 | |
| SCHEMBL200500 | 0.87 | SLC6A2 (0.56) | SLC6A2SLC6A3CNR2 | |
| SCHEMBL3474323 | 0.86 | CNR2 (0.51) | CNR2 | |
| Hydrochloric Acid SCHEMBL3372120 | 0.85 | SLC6A2 (0.54) | SLC6A2SLC6A3CNR2 | |
| SCHEMBL13113832 | 0.84 | SLC6A2 (0.53) | SLC6A2SLC6A3CNR2 | |
| SCHEMBL13068043 | 0.83 | CNR2 (0.57) | CNR2 | |
| SCHEMBL13068718 | 0.83 | CNR1 (0.54) | SLC6A2SLC6A3CNR2 | |
| Hydrochloric Acid SCHEMBL3371287 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A3CNR2 | |
| SCHEMBL13068042 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A3CNR2 | |
| SCHEMBL27614702 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| CN-1956949-A | Substituted sulfonamides | MERCK & CO INC (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1871208-A | Arylalkyl amines as cannabinoid receptor modulators | MERCK & CO INC (US) | 2006-11-29 | — | — | CN | disclosed |
| US-5777150-A | Substituted amic acid derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-07-07 | — | — | US | disclosed |
| EP-0611749-B1 | Substituted amic acid derivatives useful for treatment of arteriosclerosis | BANYU PHARMA CO LTD (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5616803-A | EXHIBIT SQUALENE SYNTHASE-INHIBITORY ACTIVITIES; USEFUL IN TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA, HYPERLIPEMIA AND ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-04-01 | — | — | US | disclosed |
| US-5606101-A | INTERMEDIATES FOR SQUALENE SYNTHASE INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5488149-A | SQUALENE SYNTHASE INHIBITORS AS ANTICHOLESTEROL OR ANTILIPEMIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-01-30 | — | — | US | disclosed |
| EP-0611749-A1 | Substituted amic acid derivatives useful for treatment of arteriosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | SLC6A2 1525/4885SLC6A3 2303/4885CNR2 2/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | SLC6A2 1525/4885SLC6A3 2303/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.